Our Mission
Contribute to the health and future
of cancer patients and their families
through the development of novel biologically targeted radiation therapy
CEO
Masatoshi Chiba, PhD
Experience in pharma for over 35 years.
Expertise in Management Strategies, DDS & CMC, Production and SCM
Management of UK/EU Subsidiaries as President and Representative Director
Pioneering the Future of Cancer Treatment !
We are working to develop new treatment methods to face cancer.
Cancer still has a major impact on the lives of many people, and even with current medical treatment, there are many cases where a complete cure is difficult. Conventional treatment methods have their limitations, and there is a need for methods that are more effective and less burdensome for patients. We are focusing on boron neutron capture therapy (BNCT), an advanced radiation therapy that can selectively attack only cancer cells and has the potential to complete the treatment in a single session and a single day.
RadioNano Therapeutics,Inc., a drug discovery venture originating from Kyoto University, is developing a new drug, RN-501, which will further advance BNCT by using nanoparticles to increase uptake into cancer tissue, aiming for safer and more effective treatment. We are accelerating preparations for practical application of the drug based on the fund raising completed in 2024.
We will continue to take on the challenge, hoping that BNCT and RN-501 will become new options to improve the quality of life (QOL) of people fighting cancer.
We look forward to your continued warm support.
RadioNano Therapeutics, Inc.
Representative Director, President and CEO
Masatoshi Chiba, Ph.D.
The two overlapping hexagons represent “BNCT” and “nanotechnology,” respectively, and their overlapping symbolizes the image of shining light.
We aim to bring new possibilities to cancer treatment through this therapy born from the encounter of BNCT and nanotechnology, and to serve as a reliable light for cancer patients and their families.
Mission
Contribute to the health and future
of cancer patients and their families
through the development of novel biologically targeted radiation therapy
Vision
Aim to be a research-based global innovation company that discovers and delivers new BNCT drugs to cancer patients.
Values
Integrity, Agility, Innovation, Passion
Members
CBO/COO
Hiroshi Kawai, PhD
Experience in pharma for over 30 years.
Expertise in Pharmacology and BD
Management of US Subsidiaries as VP
Management of biotech venture as CEO
Independent Director
Hiroyuki Ueno, PhD
Kyoto University Innovation Capital Co., Ltd. (Kyoto iCAP)
Scientific Advisory Committee
Minoru Suzuki, MD PhD
Institute for Integrated Radiation and Nuclear Science,
Kyoto University
Independent Director
Prof. Naoki Komatsu, PhD
Graduate School of Human and Environmental Studies,
Kyoto University
Outside Auditor
Hirotsugu Wakatake
Partner attorney at Oike General Law Office
RadioNano Therapeutics Inc.
Headquarters: 36-1 Yoshidahonmachi, Sakyo-ku, Kyoto, JAPAN 606-8501
Establishment: April 1, 2024
Capital： 236,977,500 JPY
Representative: CEO Masatoshi Chiba
Stockholders： Kyoto University Innovation Capital Corporation, Mitsubishi UFJ Capital Co. Ltd., DBJ Capital Co. Ltd., Japan Science and Technology Agency.